What Is KLOW?
KLOW combines two research agents with distinct anti-inflammatory mechanisms into a single compound: KPV (Lysine-Proline-Valine), a tripeptide fragment of the C-terminal sequence of alpha-MSH, and low-dose naltrexone (LDN). Together, they represent a dual-mechanism approach to studying inflammatory pathways, particularly in the context of gut and mucosal inflammation research.
The KPV Component
Mechanism of Action
KPV is the C-terminal tripeptide of alpha-MSH (α-MSH) and has been shown to retain the anti-inflammatory properties of the full peptide despite its smaller size. It acts through melanocortin receptors — primarily MC1R and MC3R — and has been documented to inhibit NF-κB activation, reduce pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6), and modulate the TGF-β signaling pathway.
Gut Inflammation Research
KPV has shown particular promise in gut inflammation models. Studies in rodent models of colitis demonstrate that KPV can reduce macroscopic and microscopic colitis scores, lower inflammatory cytokine levels in colon tissue, and improve epithelial barrier function. These findings have driven interest in KPV as a tool for studying inflammatory bowel pathology.
The Low-Dose Naltrexone (LDN) Component
LDN Mechanism
Naltrexone is a full opioid receptor antagonist approved at high doses for opioid dependence. At low doses (typically 1–4.5 mg in human clinical research), naltrexone exhibits a paradoxical immune-modulating effect. The proposed mechanism involves transient opioid receptor blockade triggering a rebound upregulation of endogenous opioid production, as well as direct antagonism of Toll-Like Receptor 4 (TLR4) on microglia and macrophages — independent of opioid receptors.
LDN Research Areas
LDN has been studied in multiple inflammatory and autoimmune contexts including Crohn's disease, multiple sclerosis, fibromyalgia, and various autoimmune conditions. The TLR4 antagonism pathway is considered particularly relevant for neuroinflammatory conditions.
Combined KPV + LDN Research Rationale
The research rationale for combining KPV and LDN centers on complementary and potentially synergistic anti-inflammatory mechanisms: KPV addresses cytokine and NF-κB pathways via melanocortin receptor engagement, while LDN modulates innate immune activation via TLR4 antagonism. Together, they offer a tool for studying multi-pathway inflammation suppression in gut and systemic models.
Research Summary
| Component | Model | Key Observation |
|---|---|---|
| KPV — Colitis | Mouse DSS colitis | Reduced colitis score, lower TNF-α in colon tissue |
| KPV — Cytokines | In vitro macrophages | Downregulation of IL-1β, IL-6, TNF-α |
| LDN — Crohn's | Human clinical | Reduced CDAI scores (small pilot studies) |
| LDN — Neuroinflammation | Mouse MS model | Reduced microglial activation |
| LDN — TLR4 | In vitro | Direct TLR4 antagonism independent of opioid receptors |
Storage
Store KLOW at −20°C, protected from light and moisture. Follow standard peptide storage procedures for reconstitution.
For research use only. Not for human or animal use. Order KLOW here.